NCT05070247 - A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 14, 2022

Primary Completion Date

January 6, 2025

Study Completion Date

January 6, 2025

Conditions

Pancreatic CancerHepatocellular CancerMesotheliomaBreast CancerGastric CancerEsophageal CancerNasopharyngeal CancerKidney CancerSquamous Cell Cancer of Head and Neck (SCCHN)Non-small Cell Lung Cancer (NSCLC), Non-squamous

Interventions

DRUG

TAK-500

TAK-500 intravenous infusion.

DRUG

Pembrolizumab

Pembrolizumab intravenous infusion.

Trial Locations (12)

19111

Fox Chase Cancer Center, Philadelphia

33136

Sylvester Comprehensive Cancer Center, Miami

35294

Univeristy of Alabama at Birmingham, Birmingham

37203

Sarah Cannon Cancer Institute, Nashville

60611

Northwestern, Chicago

78229

START South Texas Accelerated Research Therapeutics, San Antonio

80045

University of Colorado - Anschutz Medical Campus - PPDS, Aurora

80218

Sarah Cannon Research Institute, Denver

91010

City of Hope Comprehensive Cancer Center, Duarte

92093

University of California San Diego, La Jolla

02215

Dana Farber Cancer Institute, Boston

10016-4744

New York University, New York